Payment overview · 2025
General Payments
$103,629.89
168 reported records · 7 companies
Healthcare provider profile · identity verified
Jonathan Clavell Hernandez, MD
Allopathic & Osteopathic Physicians|Urology · HOUSTON, TX · NPI 1619230869
Verified facts
What the public records show
CMS Open Payments records show Jonathan Clavell Hernandez, MD received $103,629.89 in general payments during 2025 across 168 reported records.
COLOPLAST CORP accounted for 83.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Xyosted.
Antares Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYOSTED as an associated drug or biological on 18015 records involving 7619 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Xyosted by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| COLOPLAST CORP | Unresolved — no canonical attribution shown | $86,125.84 | 83.1% | 118 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $16,884.94 | 16.3% | 30 | 2025 |
| Endo USA, Inc. | Unresolved — no canonical attribution shown | $365.04 | 0.3% | 12 | 2025 |
| Valencia Technologies Corporation | Unresolved — no canonical attribution shown | $127.49 | 0.1% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $93.97 | 0.1% | 5 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $17.35 | 0.0% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $15.26 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $79,892.00 | 16 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,849.00 | 11 |
| Food and Beverage | $5,850.23 | 131 |
| Travel and Lodging | $2,038.66 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Titan Normalized: titan |
Device | COLOPLAST CORP | $80,733.84 | 115 | 2025 |
Source payment records
|
|||||
| AMS 700 CXR RTE Kit Normalized: ams 700 cxr rte kit |
Device | Boston Scientific Corporation | $11,844.00 | 8 | 2025 |
Source payment records
|
|||||
| General - Erectile Dysfunction Normalized: general erectile dysfunction |
Device | Boston Scientific Corporation | $4,787.09 | 17 | 2025 |
Source payment records
|
|||||
| SenSura Mio Normalized: sensura mio |
Device | COLOPLAST CORP | $580.00 | 2 | 2025 |
Source payment records
|
|||||
| XIAFLEX Normalized: xiaflex |
Biological | Endo USA, Inc. | $365.04 | 12 | 2025 |
Source payment records
|
|||||
| AMS 700 Normalized: ams 700 |
Device | Boston Scientific Corporation | $253.85 | 5 | 2025 |
Source payment records
|
|||||
| eCoin Device Kit Normalized: ecoin device kit |
Device | Valencia Technologies Corporation | $127.49 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $93.97 | 5 | 2025 |
Source payment records
|
|||||
| UROLIFT Normalized: urolift |
Device | Teleflex LLC | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $15.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| XYOSTED xyosted |
2025 | Xyosted | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Antares Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | XYOSTED open payments reported associated product |
CMS Open Payments — General Payments 18015 supporting records · 7619 recipient NPIs · example record 1235880452 |
Xyosted · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Tamsulosin Hcl | Tamsulosin Hcl | 154 | 78 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 93 | 85 |
| Gabapentin | Gabapentin | 69 | 61 |
| Cephalexin | Cephalexin | 68 | 63 |
| Testosterone Cypionate | Testosterone Cypionate | 38 | 16 |
| Cabergoline | Cabergoline | 29 | 14 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 27 | 26 |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Xyosted | Testosterone Enanthate | 18 | suppressed |
| Tadalafil | Tadalafil | 17 | suppressed |
| Testosterone | Testosterone | 17 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $103,629.89 · 168 records | COLOPLAST CORP | AMS 700, AMS 700 CXR RTE Kit, General - Erectile Dysfunction, JATENZO, SenSura Mio, Titan, UROLIFT, XIAFLEX, XYOSTED, eCoin Device Kit | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Xyosted play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Antares Pharma, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error